Barclays Has Lowered Expectations for Certara (NASDAQ:CERT) Stock Price

Certara (NASDAQ:CERT) had its price objective reduced by equities research analysts at Barclays from $13.00 to $11.00 in a report issued on Thursday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Barclays‘s target price suggests a potential upside of 20.88% from the stock’s previous close.

Other analysts have also issued research reports about the stock. William Blair restated a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Stephens reiterated an “overweight” rating and issued a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. Finally, TD Cowen began coverage on shares of Certara in a research report on Thursday, February 27th. They issued a “buy” rating and a $16.00 price objective on the stock. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $15.50.

Certara Stock Down 6.5 %

Shares of CERT traded down $0.63 during mid-day trading on Thursday, reaching $9.10. 203,256 shares of the stock traded hands, compared to its average volume of 1,082,777. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of -45.50, a P/E/G ratio of 9.29 and a beta of 1.64. The stock has a fifty day simple moving average of $11.69 and a 200 day simple moving average of $11.35. Certara has a 12-month low of $8.64 and a 12-month high of $18.68. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Institutional Trading of Certara

A number of hedge funds and other institutional investors have recently made changes to their positions in CERT. Versant Capital Management Inc raised its position in shares of Certara by 218.8% during the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock worth $27,000 after buying an additional 1,866 shares in the last quarter. Venturi Wealth Management LLC raised its holdings in shares of Certara by 839.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after purchasing an additional 2,509 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock worth $34,000 after purchasing an additional 1,047 shares in the last quarter. Johnson Financial Group Inc. bought a new stake in shares of Certara in the 4th quarter worth approximately $47,000. Finally, Blue Trust Inc. raised its holdings in shares of Certara by 20.9% in the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after purchasing an additional 822 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.